How to access Amvuttra from India — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian patient — or a diaspora family supporting a relative in Chennai, Mumbai, Hyderabad, or Bengaluru — diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Amvuttra (vutrisiran) from their treating neurologist. Amvuttra is FDA-approved for this indication and developed by Alnylam Pharmaceuticals. It is not routinely stocked through the Indian domestic supply chain for outpatient dispensing, which is why neurology teams at AIIMS, CMC Vellore, Medanta, Apollo, and other tertiary amyloid centres often coordinate access through the personal-use or hospital-sponsored named-patient import pathway.

This guide explains the legal pathway, the documentation your neurologist prepares, typical timing, indicative cost posture, and where Reserve Meds fits in.

The clinical situation

Amvuttra is a subcutaneous small interfering RNA (siRNA) therapy that silences hepatic TTR production. It is administered once every three months by subcutaneous injection — a practical advantage in India, where infusion-chair infrastructure and travel distance to tertiary centres are real constraints for families. Eligibility is anchored in genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy (sensory, motor, or autonomic), and exclusion of confounding diagnoses. Your neurologist will establish baseline neuropathy impairment scoring (NIS or NIS+7), modified body mass index (mBMI), polyneuropathy disability score, and a cardiac workup — ECG, echocardiogram, NT-proBNP — to characterise any ATTR-CM overlap. Amvuttra is given in-clinic by a trained clinician; no infusion suite, no premedication regimen.

Is Amvuttra legally importable into India?

Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. India has a mature personal-use mechanism that has supported rare-disease access for many years. A registered medical practitioner — or the patient themselves, on personal-use grounds with physician documentation — may request import of a medicine approved by a recognised reference authority such as the US FDA when no clinically equivalent registered alternative exists. hATTR polyneuropathy has limited disease-specific registered options in India, which supports clinical rationale.

How the pathway works, step by step

1. Consultation with your treating neurologist. TTR genetic report, neuropathy impairment scoring, and a clinical rationale documenting the absence of equivalent registered alternatives.
2. Baseline assessment. NIS/NIS+7, polyneuropathy disability score, mBMI, cardiac workup (ECG, echocardiogram, NT-proBNP), and renal/hepatic panels.
3. CDSCO personal-use / named-patient application. The physician or hospital pharmacy files clinical rationale, genetic report, patient identification, and product details.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Amvuttra from authorised distribution under DSCSA.
5. Cold-chain shipment. Amvuttra requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging and customs clearance support.
6. Arrival and administration. The hospital pharmacy receives the product; the neurology clinic administers the subcutaneous dose and schedules the next quarterly visit.

What documentation your physician needs

• Clinical rationale letter confirming hATTR polyneuropathy and Amvuttra as the indicated therapy
• Verification of Indian medical registration (NMC / state medical council)
• TTR genetic test result from an accredited laboratory
• Baseline NIS/NIS+7 and polyneuropathy disability score
• Cardiac assessment for ATTR-CM overlap
• Planned dosing schedule (every 3 months) and long-term monitoring plan

Reserve Meds provides a physician documentation kit bundling the templates CDSCO reviewers and Indian customs officers typically expect for rare-disease named-patient imports.

Costs and timing

Amvuttra for hATTR polyneuropathy is a substantial therapy. Reference US cash-pay for a full annual course (four quarterly doses) typically sits in the high six-figure USD range. Reserve Meds operates on a drug-only reference basis and provides a transparent, itemised delivered quote — covering product, cold-chain logistics, CDSCO documentation handling, customs clearance, and concierge coordination — at the start of intake. Figures are indicative, not a binding quote until intake is complete.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete CDSCO application is submitted and customs processing begins. Subsequent quarterly doses ship on a scheduled cadence once the pathway is established.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: hATTR is autosomal-dominant, and Indian families often coordinate care decisions across generations and continents — a parent in Chennai, a sibling in New Jersey, a cousin in Dubai. Our concierge coordinates with whichever family members the patient designates and accepts diaspora payment.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and CDSCO / customs review.
• Logistics. Validated cold-chain shipment with customs clearance support.
• Concierge case lead. A named point of contact for long-term quarterly refills.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. See our trust and compliance page.

How is Amvuttra different from Onpattro or Wainua? All three address hATTR polyneuropathy but differ in mechanism and administration. Amvuttra is subcutaneous siRNA given once every three months. Onpattro is intravenous siRNA given every three weeks with a premedication regimen. Wainua is a subcutaneous antisense oligonucleotide given monthly. Your neurologist selects based on the clinical picture, patient preference, and logistics.

Can diaspora family pay directly? Yes. Cross-border payment is common; we issue invoicing that family members in the US, UK, UAE, Canada, Australia, and Singapore can settle directly.

Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Amvuttra coordination in India.

Add me to the Amvuttra waitlist

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.